ELMSFORD, NY --(Marketwired - December 05, 2017) - NanoVibronix, Inc. (
Brian Murphy, Chief Executive Officer of NanoVibronix Inc., commented, "We are excited to report our first European distributor on the heels of our recent interim trial results for patients with Trigeminal Neuralgia. We believe this study, along with our earlier clinical trial results, illustrate the ability of PainShield™ to help treat challenging patient populations, and potentially eliminate or reduce the need for opioids across many indications. The European Monitoring Centre for Drugs and Drug Addiction reported that the United Kingdom accounted for 31 percent of Europe's 8,441 overdose deaths in 2015. This is a staggering number and reinforces the need to reduce the use of opioids and other systemic painkillers, which simply mask pain. In contrast, PainShield™ is an ultrasound-based product designed to treat pain in nerves, muscles, joints and soft tissue through delivery of localized ultrasound, which induces soft tissue healing in targeted areas."
Bharat Vadukul, Director of BHR Pharmaceuticals Ltd. commented, "Given the strong supporting clinical data, including the recent interim trial results for the PainShield™ device in treating patients with Trigeminal Neuralgia, we look forward to offering PainShield™ through our network of both healthcare professionals and direct-to-consumer, as a means to help reduce the need for opioids and other systemic medications, as well as reduce the need for surgery in many patients."
About NanoVibronix
NanoVibronix Inc. (
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise..
Investor Contacts: Crescendo Communications and Hayden IR naov@crescendo-ir.com 212-671-1021 hart@haydenir.com 917-658-7878
